Since both ROS1 and ALK share a similar homology, crizotinib, a therapy originally generated to target ALK-positive NSCLC was repurposed for treating NSCLCs with ROS1 rearrangements. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.